Stocks Health care ADCT
NYSE · Health careADC Therapeutics SA (ADCT)
ADC Therapeutics SA brought in $84.9M of revenue over the twelve months to September 30, 2026, up 12.8% from a year earlier. It posted a net loss of $81.2M. In fiscal 2025 capital spending exceeded operating cash flow by $141.4M. At September 30, 2026 it held $189.2M in cash against $7.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about ADC Therapeutics SA
- Net worth
- ADC Therapeutics SA has a market value (market cap) of $192.8M at the latest share price, and shareholders' equity of -$249.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $81.4M (+14.9% year on year), with a net loss of $142.6M. Over the 12 months to September 30, 2026: revenue $84.9M, net loss $81.2M.
- Cash flow
- In fiscal 2025 operations used $141.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- ADC Therapeutics SA's next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What ADC Therapeutics SA does
ADC Therapeutics SA is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker ADCT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $81.4M | -$142.6M | -$1.12 | -$141.4M |
| 2024 | $70.8M | -$157.8M | -$1.62 | -$124.7M |
| 2023 | $69.6M | -$240.1M | -$2.94 | -$121.9M |
| 2022 | $209.9M | -$157.1M | -$2.01 | -$139M |
| 2021 | $33.9M | -$230M | n/a | -$236.8M |
| 2020 | $0 | -$246.3M | -$3.77 | -$169.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ADCT ranks in Health care
Latest SEC filings
What ADC Therapeutics SA has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 32% to $21.7M versus the same quarter last year; diluted EPS -$0.16 versus -$0.30.
- November 9, 2026
- November 4, 2026
- November 3, 2026
- October 29, 2026Passive stake (5% or more) SCHEDULE 13G
- October 13, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 2.2% to $19.2M versus the same quarter last year; diluted EPS -$0.11 versus -$0.50.
- August 13, 2026
Insider trades
What the people running ADC Therapeutics SA did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 30, 2026 | Mallik AmeetChief Executive Officer, Director | Received as pay | 675,000 | - |
| June 30, 2026 | Carmona JoseChief Financial Officer | Received as pay | 203,700 | - |
| June 30, 2026 | Graham Peter JChief Legal Officer | Received as pay | 221,100 | - |
| June 30, 2026 | Zaki MohamedChief Medical Officer | Received as pay | 213,900 | - |
| June 3, 2026 | Coughlin TimothyDirector | Shares withheld for tax | 12,600 | $38.8K |
| June 3, 2026 | Bizzari Jean-PierreDirector | Shares withheld for tax | 12,600 | $38.8K |
| June 3, 2026 | Hug PeterDirector | Shares withheld for tax | 2,156 | $6.6K |
| June 3, 2026 | Monges VivianeDirector | Shares withheld for tax | 2,596 | $8K |
Who owns ADCT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bain Capital Life Sciences Opportunities IV, L.P.13G, passive | 9.99% | October 29, 2026 |
| Redmile Group, LLC13G, passive with 3 related filers | 9.9% | April 24, 2026 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 9.69% | August 14, 2026 |
| Dr. Hans-Peter Wild13G, passive with 2 related filers | 9.61% | May 19, 2025 |
| TCG Crossover GP II, LLC13G, passive with 2 related filers | 9.2% | February 17, 2026 |
| Prosight Management, LP13G, passive with 4 related filers | 6.8% | February 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 114 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 24,652,368 | +19,054,935 |
| Redmile Group, LLC | 11,526,710 | -3,943,792 |
| TCG Crossover Management, LLC | 11,390,175 | 0 |
| Prosight Management, LP | 7,824,749 | -475,251 |
| BlackRock, Inc. | 7,020,093 | +769,346 |
| Point72 Asset Management, L.P. | 3,649,144 | +267,015 |
| Morgan Stanley | 3,051,173 | -761,409 |
| Millennium Management LLC | 2,899,535 | -219,619 |
| Citadel Advisors LLC | 2,053,316 | +1,653,595 |
| Goldman Sachs Group Inc | 1,914,424 | +261,398 |
| State Street Corp | 1,685,836 | +119,174 |
| Geode Capital Management, LLC | 1,445,546 | +241,790 |
| Bank of America Corp | 1,288,206 | -36,811 |
| Vanguard Portfolio Management LLC | 897,092 | -136,185 |
| Two Sigma Investments, LP | 773,414 | +105,392 |
| Blue Owl Capital Holdings LP | 733,568 | 0 |
| D. E. Shaw & Co., Inc. | 719,320 | +476,144 |
| Opaleye Management Inc. | 700,000 | new |
| Aqr Capital Management LLC | 658,125 | +420,488 |
| Bnp Paribas Financial Markets | 652,849 | -207,642 |
Insiders
13 insiders reported holding 28,896,469 shares in total, about $43.6M at the last price.
| Holder | Shares |
|---|---|
| Redmile Group, LLC10% owner | 22,932,02812,666,731 held indirectly |
| Mallik AmeetChief Executive Officer, Director | 2,121,769 |
| Carmona JoseChief Financial Officer | 938,076 |
| Zaki MohamedChief Medical Officer | 896,317 |
| Graham Peter JChief Legal Officer | 841,640 |
| Hug PeterDirector | 263,344 |
| Monges VivianeDirector | 186,447 |
| Sandor VictorDirector | 140,686 |
| Bizzari Jean-PierreDirector | 139,302 |
| Kallebo Lisa MichelleChief Accounting Officer | 128,224 |
Questions about ADCT
What does ADC Therapeutics SA do?
ADC Therapeutics SA is a company in the Health care sector, listed on NYSE as ADCT. Its shares trade on NYSE under the ticker ADCT.
What is ADC Therapeutics SA's net worth?
ADC Therapeutics SA has a market value (market cap) of $192.8M at the latest share price, and shareholders' equity of -$249.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is ADC Therapeutics SA profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $81.2M on revenue of $84.9M.
How much revenue does ADC Therapeutics SA make?
Over the twelve months to September 30, 2026 ADC Therapeutics SA reported revenue of $84.9M. That is 12.8% more than a year earlier.
When did ADC Therapeutics SA last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is ADC Therapeutics SA's next earnings report?
ADC Therapeutics SA's next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ADCT with
Follow ADCT
Get an email when ADC Therapeutics SA files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values ADC Therapeutics SA tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.